Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 vs TPC in HR+/HER2- Breast Cancer
NCT06081959Phase 3Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in breast cancer (2 arms), sponsored by Kelun-Biotech. Primary endpoint: Progression-Free Survival at 24 months. Started Oct 2023; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06081959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081959.